The combination of endoglin and FIB-4 increases the accuracy of detection of hepatic fibrosis in chronic hepatitis C patients

Dawlat Salem, Magdy El-Serafy, Eman Obeida, Wafaa Al-Akel, Maissa El-Raziki, Dina Attia, Mostafa Hassan

Biochemistry Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Endemic Medicine Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.
Endemic Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt.

DOI: 10.4236/ojgas.2012.22013                

Abstract

Background and aim: In patients infected with chronic hepatitis C virus, liver biopsy is the gold standard method of staging fibrosis. Different combinations of serum markers attempted to correlate with hepatic fibrosis in place of liver biopsy and have shown encouraging results. The aim of our study is to evaluate the diagnostic value of endoglin and FIB-4 as non-invasive markers of hepatic fibrosis in HCV patients. Methods: We estimated serum endoglin & FIB-4 index in 40 infected chronic hepatitis C patients. Histological staging of hepatic fibrosis was done according to the METAVIR scoring system. Results: Both endoglin and FIB-4 index showed positive correlation with age and aspartate transaminase and inverse correlation with albumin. The diagnostic performance determined by AUROCs for early fibrosis (≤F2), was 0.868 for endoglin and 0.887 for FIB-4, at cut off va- lues of 5.5 & 0.98 with sensitivity of 64.3% & 82.1%, and specificity of 100% & 85% respectively. For ad-vanced fibrosis (>F2), the AUROC was 0.98 for endoglin and 0.967 for FIB-4, obtained at cut off values of 6.29 & 1.6, with sensitivity of 100% & 91.7%, and specificity of 89.3% & 92.9%, respectively. Conclusion: Both serum endoglin and FIB-4 index are fairly accurate in differentiating stages of hepatic fibrosis; their combination in a single equation enhanced the accuracy of fibrosis detection in chronic HCV patients.

Keywords

Hepatitis C Virus; Hepatic Fibrosis; Liver Biopsy; Non-Invasive Marker; Endoglin; FIB-4

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	WHO (2002) NIH consensus statement on management of hepatitis C. Hepatology, 36, 3-20. doi:10.1053/jhep.2002.37117
[2]	Parkes, J., Guha, I., Roderick, P. and Rosenberg, W. (2006) Performance of serum marker panels for liver fibrosis in chronic hepatitis C. Journal of Hepatology, 44, 462-474. doi.org/10.1016/j.jhep.2005.10.019
[3]	Cadranel, J., Rufat, P. and Degos, F., (2000) Practices of liver biopsy in France: Results of a prospective nationwide survey. Journal of Hepatology, 32, 477-481. doi:10.1053/jhep.2000.16602
[4]	Patel, K., Gordon, S., Jacobson, I., et al. (2004) Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. Journal of Hepatology, 41, 935-942. doi.org/10.1016/j.jhep.2004.08.008
[5]	Levoy, V., Hilleret, M.N., Sturm, N., et al. (2007) Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. Journal of Hepatology, 46, 775-782. doi.org/10.1016/j.jhep.2006.12.013
[6]	Westin, J., Ydreborg, M., Islam, S., et al. (2008) A non-invasive fibrosis score predicts treatment outcome in chro- nic hepatitis C virus infection. Scandinavian Journal of Gastroenterology, 43, 73-80. doi:10.1080/00365520701514461
[7]	Vallet-Pichard, A., Mallet, V., Nalpas, B., et al. (2007) FIB-4: An Inexpensive and accurate marker of fibrosis in HCV infection. Hepatology, 46, 32-36. doi:10.1002/hep.21669
[8]	The French METAVIR Cooperative Study Group (1994) Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Journal of Hepatology, 20, 15-20.
[9]	Esmat, G., Metwally, M., Zalata, K., et al. (2007) Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C. Journal of Hepatology, 46, 620-627. doi.org/10.1016/j.jhep.2006.12.010
[10]	Lebrin, F., Goumans, M.J., Jonker, L., et al. (2004) Endoglin promotes endothelial cell proliferation and TGF- beta/ALK1 signal transduction. The EMBO Journal, 23, 4018-4028. doi:10.1038/sj.emboj.7600386
[11]	Bissell, D.M., Roulot, D. and George, J. (2001) Transforming growth factor b and the liver. Hepatology, 34, 859-867. doi:10.1053/jhep.2001.28457
[12]	Roy-Chaudhury, P., Simpson, J.G. and Power, D.A. (1997) Endoglin, a transforming growth factor-beta-binding protein, is upregulated in chronic progressive renal disease. Experimental Nephrology, 5, 55-60.
[13]	Pérez-Barriocanal, F., Docherty, N.G., Miguel Arévalo, M., et al. (2011) Endoglin upregulation in the liver after bile duct ligation in rats. Open Gastroenterology Journal, 5, 1-9. doi:10.2174/1874259901105010001
[14]	Yagmur, E., Rizk, M., Stanzel, S., et al. (2007) Elevation of endoglin (CD105) concentrations in serum of patients with liver cirrhosis and carcinoma. European Journal of Gastroenterology & Hepatology, 19, 755-761. doi:10.1097/MEG.0b013e3282202bea
[15]	Clemente, M., Núňez, O., Lorente, R., et al. (2006) Increased intrahepatic and circulating levels of endoglin, a TGF-?1 co-receptor in patients with chronic hepatitis C virus infection: Relationship to histological and serum markers of hepatic fibrosis. Journal of Viral Hepatitis, 13, 625-632. doi:10.1111/j.1365-2893.2006.00733.x
[16]	Kanzler, S., Baumann, M., Schirmacher, P., et al. (2001) Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. Journal of Viral Hepatitis, 8, 430-437. doi:10.1046/j.1365-2893.2001.00314.x
[17]	Snyder, N., Nguyen, A., Gajula, L., et al. (2007) The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C. Clinica Chimica Acta, 381, 119-123. doi.org/10.1016/j.cca.2007.02.046.
[18]	Grigorescu, M. (2006) Noninvasive biochemical markers of liver fibrosis. Journal of Gastrointestinal and Liver Diseases, 15, 149-159.
[19]	Sebastiani, G., Vario, A., Guido, M., et al. (2006) Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. Journal of Hepatology, 44, 686-693. doi.org/10.1016/j.jhep.2006.01.007
[20]	Imbert-Bismut, F., Ratziu, V., Pieroni, L., et al. (2001) Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet, 357, 1069-1075. doi.org/10.1016/S0140-6736(00)04258-6
[21]	Poynard, T., McHutchison, J., Manns, M., Rob, P., Myers Albrecht, J. (2003) Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology, 38, 481- 492. doi:10.1053/jhep.2003.50319
[22]	Cales, P., Oberti, F., Michalak, S., et al. (2005) A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology, 42, 1373-1381. doi:10.1002/hep.20935